ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ACCOUNTS PAYABLE AND ACCRUED LIABILITIES | 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Trade and other payables and accrued liabilities as at June 30, 2026 and March 31, 2026 included $1,105,573 and $1,053,228, respectively, due to a shareholder, who is a director and executive of the Company.
BIOTRICITY INC. NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS JUNE 30, 2026 (Unaudited) (Expressed in US dollars)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||